# Study: COVID Could Be Treated for Less than $1 a Day

Live Trading News is an independent financial media publication. Masthead: Live Trading News. Parent: Knightsbridge Group. Product cousin: KXCO (kxco.ai). Coverage: markets, policy, AI, quantum, blockchain, FX, biotech, ASEAN. New stories are signed ML-DSA-65 and anchored on Armature L1; articles published before the platform launch are not signed. Nothing on the site is investment advice.

Canonical HTML: https://www.livetradingnews.com/study-covid-could-be-treated-for-less-than-1-a-day
Last modified: 2021-08-05

---

By Paul Ebeling · 2021-08-05
Tags: CO, Health, treatment, Paul Ebeling, Coronavirus, Covid, Covid19, ivermectin
Signed: no (published before platform launch).
Nothing in this article is investment advice.

#COVID #treatment #ivermectin

[$MRK ](https://finance.yahoo.com/quote/MRK?p=MRK&.tsrc=fin-srch)

A double-blind study of an antiparasitic drug that’s been in the news a lot lately not only shows that the drug can reduce the duration and infectiousness of COVID-19, but can do all that on less than $1 a day.

That drug is ivermectin, and Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba, says his studies, recently published on RXiv, show it is a cost-effective treatment that can help shorten the infection period. Dr. Schwartz studied 89 volunteers diagnosed with the virus, 50% received ivermectin; the other 50%, a placebo.

“*Nearly 72% of volunteers treated with ivermectin tested negative for the virus by Day 6,”* The Jerusalem Post reported. “*In contrast, only 50% of those who received the placebo tested negative.”* And, besides feeling better quicker, fewer ivermectin patients also were found to be infectious: 13%, compared to 50% of the placebo group.

The findings also showed that *“there is almost a 100% chance that a person will be noninfectious in four to 6 days,*” Dr. Schwartz said.

Ivermectin is an inexpensive drug that was approved by the US FDA in Y 1987 for treatment of a parasitic roundworm.

The loudest opposition to ivermectin has come from Merck Co ([NYSE:MRK](NYSE:MRK)), which manufactured the drug in the 1980s. 

In a public statement about ivermectin on its website in February, it said: “*Company scientists continue to carefully examine the findings of all available and emerging studies of ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to date, our analysis has identified no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and a concerning lack of safety data in the majority of studies.”* 

Merck has not launched any studies of its own on ivermectin.

Have a healthy, prosperous day, Keep the Faith!

---

This Markdown mirrors https://www.livetradingnews.com/study-covid-could-be-treated-for-less-than-1-a-day. The HTML page is canonical.
Site index for AI clients: https://www.livetradingnews.com/llms.txt